Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Down 55.9% in January

Appili Therapeutics Inc. (OTCMKTS:APLIF) saw a large drop in short interest in January. As of January 15th, there was short interest totalling 13,800 shares, a drop of 55.9% from the December 31st total of 31,300 shares. Based on an average daily volume of 40,400 shares, the short-interest ratio is currently 0.3 days.

Appili Therapeutics Stock Performance

APLIF stock remained flat at $0.02 during trading hours on Friday. The business has a fifty day moving average of $0.03 and a two-hundred day moving average of $0.03. Appili Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.05. The firm has a market capitalization of $2.81 million, a P/E ratio of -1.16 and a beta of -0.52.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.